<DOC>
	<DOCNO>NCT00421889</DOCNO>
	<brief_summary>The study seek assess safety , pharmacodynamics , pharmacokinetics efficacy belinostat ( PXD101 ) administer combination carboplatin paclitaxel patient solid tumour follow maximum tolerate dose ( MTD ) expansion ( phase II ) ovarian bladder cancer patient The clinical trial MTD ( phase II ) portion study enrol bladder cancer patient . Enrollment ovarian patient complete .</brief_summary>
	<brief_title>A Study Belinostat + Carboplatin Paclitaxel Both Patients With Ovarian Cancer Need Relapse Treatment</brief_title>
	<detailed_description>MTD Expansion I ( Phase II ) : A total 18-32 patient epithelial ovarian , primary peritoneal , fallopian tube mixed mullerian tumour ovarian origin , need relapse treatment enrol . MTD Expansion II ( phase II ) : A total 15 patient urothelial ( transitional cell ) carcinoma bladder enrol .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Belinostat</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>1 . Signed consent IRB ( Institutional Review Board ) approve consent form . 2 . Patients histologically confirm solid carcinoma , know curative therapy . 3 . Performance status ( Eastern Cooperative Oncology Group [ ECOG ] ) ≤ 2 . 4 . Life expectancy least 3 month . 5 . Age ≥ 18 year . 6 . Acceptable liver , renal bone marrow function include follow : 1 . Bilirubin ≤ 1.5 time ULN ( upper limit normal ) . 2 . AST/SGOT ( [ Aspartate Amino Transferase/Serum glutamic oxaloacetic transaminase ] ) , ALT/SGPT ( [ Alanine Amino Transferase/Serum glutamic pyruvic transaminase ] ) alkaline phosphatase ≤ 3 time ULN ( liver metastasis present , ≤ 5 x ULN allow ) . 3 . Measured EDTA ( [ ethylenediaminetetraacetic acid ] ) renal clearance ≥ 45 mL/min ( EU sit ) . At US site calculate creatinine clearance ≥ 45 mL/min use Jeliffe formula . 4 . Leukocytes &gt; 2.5×109/L , neutrophil &gt; 1.0x109/L , platelet &gt; 100×109/L . 5 . Hemoglobin &gt; 9.0 g/dL &gt; 5.6 mmol/L . 7 . Acceptable coagulation status : PTINR ( [ prothrombinInternational Normalized Ratio ] ) /APTT ( [ Activated Partial Thromboplastin Time ] ) ≤ 1.5 × ULN therapeutic range anticoagulation therapy 8 . A negative pregnancy test woman childbearing potential . For men woman childproducing potential , use effective contraceptive method study require . 9 . Serum potassium within normal range ( add protocol Global version 3.0 ) Additional Eligibility Criteria MTD Expansion 10 . Patients epithelial ovarian cancer need relapse treatment . Changed protocol Global version 3 : Patients epithelial ovarian , primary peritoneal , fallopian tube mixed mullerian tumor ovarian origin need relapse treatment . Or 11 . Patients urothelial ( transitional cell ) carcinoma bladder receive maximum 3 previous chemotherapy regimen advance disease setting ( neoadjuvant chemotherapy include total chemotherapy regimen ) , apply patient enrolled Part D. 12 . At least one unidimensional measurable lesion . Lesions must measure CT scan MRI accord Response Evaluation Criteria Solid Tumors ( RECIST ) ( Added protocol Global version 4 ) . Eligibility Criteria Site Specific Amendment ( Part C ) Advanced solid tumor 13 . Patients refractory solid tumor ovarian cancer . 1 . Treatment investigational agent within last 4 week . 2 . Prior anticancer therapy within last 3 week study dose include chemotherapy , radiotherapy , endocrine therapy , immunotherapy use investigational agent . Changed protocol Global version 1 ; prior anticancer therapy within last 3 week study dose include chemotherapy , radiotherapy , endocrine therapy immunotherapy . 3 . Coexisting active infection coexist medical condition likely interfere study procedure , include significant cardiovascular disease ( New York Heart Association Class III IV cardiac disease ) , myocardial infarction within past 6 month , unstable angina , congestive heart failure require therapy , unstable arrhythmia need antiarrhythmic therapy , evidence ischemia ECG , mark baseline prolongation QT/QTc interval , e.g. , repeat demonstration QTc interval ( [ correct QT interval ] ) &gt; 500 msec ; Long QT Syndrome ; require use concomitant medication belinostat infusion day may cause Torsade de Pointes ( see Appendix 1.1 , protocol EU version 1.0 , Appendix A Appendix 16.1.1 ) . 4 . Altered mental status preclude understand informed consent process and/or completion necessary study . 5 . History concurrent second malignancy . Changed Site Specific Amendment ( Part D ) : History concurrent second malignancy . In patient urothelial ( transitional cell ) carcinoma bladder exception incidental finding localized prostate cancer time radical cystectomy preclude inclusion study . In case patient eligible inclusion Gleason score ≤6 Prostate Specific Antigen ( PSA ) &lt; 10 ng/mL ( patient would hormonal treatment PSA must undetectable ) .Only applied patient include site specific amendment . 6 . History hypersensitivity either platinum paclitaxel unable desensitize ( add protocol Global version 4 ) . 7 . More 3 prior line chemotherapy give metastatic disease ( add protocol Global version 1 ) . 8 . Bowel obstruction impend bowel obstruction . 9 . Known HIV positivity . 10 . Any Grade 2 drugrelated neurotoxicity , follow recovery . 11 . Changed protocol Global version 1 : Any exist Grade 2 drug relate neurotoxicity due prior treatment agent cause neurotoxicity . Additional exclusion criterion MTD expansion 12 . Mixed mullerian tumor intrauterine origin , add protocol Global version 3 .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Ovarian cancer</keyword>
	<keyword>Ovarian Neoplasms</keyword>
	<keyword>Primary peritoneal</keyword>
	<keyword>Epithelial ovarian</keyword>
	<keyword>Fallopian tube</keyword>
	<keyword>Bladder cancer</keyword>
	<keyword>belinostat</keyword>
	<keyword>PXD101</keyword>
	<keyword>mixed mullerian cancer ovarian origin</keyword>
</DOC>